Table 3:

Dose-response evaluation of the association between nuclear and cytoplasmic survivin and breast cancer recurrence from a population-based case control study of 1312 women age 35–69, diagnosed with Stage I–III breast cancer between 1985–2001, and registered with the Danish Breast Cancer Group.

	ER+/TAM+			ER−/TAM−
Survivin Expression	Case	Control	Adjusted OR (95%CI)	Case	Control	Adjusted OR (95%CI)
Nuclear
>75th%tile	87	87	0.95 (0.66, 1.38)	71	63	1.24 (0.76, 2.02)
50th-75th %tile	100	89	0.98 (0.81, 1.18)	37	43	1.11 (0.76, 1.42)
<50th %tile	261	277	Reference	101	91	Reference
Cytoplasmic
>75th%tile	104	118	0.98 (0.82, 1.17)	60	51	1.12 (0.69, 1.83)
50th-75th %tile	124	115	0.96 (0.68, 1.36)	55	51	1.06 (0.83, 1.35)
<50th %tile	220	220	Reference	94	95	Reference
CNR
>75th%tile	39	41	1.09 (0.59, 2.03)	20	13	2.14 (0.86, 5.29)
50th-75th %tile	30	26	1.06 (0.70, 1.60)	12	5	1.66 (0.91, 3.04)
25th-50th %tile	65	54	1.03 (0.83, 1.27)	44	54	1.29 (0.95, 1.74)
<25th %tile	42	45	Reference	43	45	Reference